NDAORALELIXIR
Approved
Oct 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNOPHYLATE is an oral elixir formulation of theophylline sodium glycinate, a xanthine derivative bronchodilator. It was approved in 1947 for respiratory conditions, likely asthma and COPD, and functions by relaxing airway smooth muscle. This is a legacy small molecule with decades of clinical use.
LOE Approaching
Approaching loss of exclusivity with modest competitive pressure (30%), indicating a mature product facing potential team consolidation or repositioning efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYNOPHYLATE offers limited near-term career growth given zero linked job postings and LOE approaching status. This role is best suited for professionals managing legacy products, executing defensive strategies, or preparing for lifecycle transitions in mature portfolios.
Brand ManagerProduct Manager
Worked on SYNOPHYLATE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.